Indication
Arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis.
Loading your page…
Respiratory Tract Infections
Marketing Authorisation Holder: Insmed Netherlands B.V.
EMA Authorisation: 27/10/2020
INN: amikacin
AI Drug & Interaction Analysis
Free account required
Ask Osler about Arikayce liposomal: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.